Antimicrobial resistance and the ethics of drug development

American Journal of Public Health

Volumn 96, Issue 11, 2006, Pages 1910-1914

  Aiello, Allison E ^a   King, Nicholas B ^b   Foxman, B ^c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; GLYCOPEPTIDE; LINCOSAMIDE DERIVATIVE; LIPOPEPTIDE; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; DRUG INDUSTRY; DRUG RESEARCH; DRUG USE; GOVERNMENT; HUMAN; INFECTION; MEDICAL ETHICS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW; ARTICLE; BIOLOGICAL WARFARE; BIOTECHNOLOGY; COMMODIFICATION; COMMUNICABLE DISEASE; CONFLICT OF INTEREST; DRUG EFFECT; DRUG SCREENING; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HEALTH SERVICE; HEALTH SERVICES RESEARCH; INFECTION CONTROL; MICROBIOLOGICAL EXAMINATION; MOTIVATION; PENICILLIN RESISTANCE; PUBLIC HEALTH; STANDARD; STAPHYLOCOCCUS AUREUS; UNITED STATES;

ANTI-BACTERIAL AGENTS; BIOTECHNOLOGY; BIOTERRORISM; COMMODIFICATION; COMMUNITY-ACQUIRED INFECTIONS; CONFLICT OF INTEREST; DRUG EVALUATION; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFECTION CONTROL; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MOTIVATION; ORGANIZATIONAL CASE STUDIES; PUBLIC HEALTH; RESEARCH SUPPORT; STAPHYLOCOCCUS AUREUS; UNITED STATES;

EID: 33750442217     PISSN: 00900036     EISSN: None     Source Type: Journal    
DOI: 10.2105/AJPH.2005.077214     Document Type: Review

References (37)

1. Lowy FD. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest. 2003;111:1265-1273.
2. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7:178-182.
3. Institute of Medicine. Antimicrobial Resistance: Issues and Options. Workshop Report. Washington DC: Forum on Emerging Infections, Division of Health Sciences Policy; 1998.
4. National Nosocomial Infections Surveillance (NNIS). National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990-May 1999, issued June 1999. Am J Infect Control 1999;27:520-532.
5. Vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR Morb Mortal Wkly Rep. 2004;53:322-323.
6. Staphylococcus aureus resistant to vancomycin - United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565-567.
7. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. MMWR Morb Mortal Wkly Rep. 1997;46:765-766.
8. Adcock PM, Pastor P, Medley F, Patterson JE, Murphy TV. Methicillin-resistant Staphylococcus aureus in two child care centers. J Infect Dis. 1998;178:577-580.
9. Herold BC, Immergluck LC, Maranan MC, et al. Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk. JAMA. 1998;279:593-598.
10. Centers for Disease Control and Prevention. Summary of notifiable diseases - United States, 1998. MMWR Morb Mortal Wkly Rep. 1999;47:ii-92.
11. Suggs AH, Maranan MC, Boyle-Vavra S, Daum RS. Methicillin-resistant and borderline methicillin-resistant asymptomatic Staphylococcus aureus colonization in children without identifiable risk factors. Pediatr Infect Dis J. 1999;18:410-414.
12. Carleton HA, Diep BA, Charlebois ED, Sensabaugh GF, Perdreau-Remington F. Community-adapted methicillin-resistant Staphylococcus aureus (MRSA): population dynamics of an expanding community reservoir of MRSA. J Infect Dis. 2004;190:1730-1738.
13. Wannet WJ, Spalburg E, Heck ME, et al. Emergence of virulent methicillin-resistant Staphylococcus aureus strains carrying Panton-Valentine leucocidin genes in the Netherlands. J Clin Microbiol. 2005;43:3341-3345.
14. Diep BA, Sensabaugh GF, Somboona NS, Carleton HA, Perdreau-Remington F. Widespread skin and soft-tissue infections due to two methicillin-resistant Staphylococcus aureus strains harboring the genes for Panton-Valentine leucocidin. J Clin Microbiol. 2004;42:2080-2084.
15. Said-Salim B, Mathema B, Braughton K, et al. Differential distribution and expression of Panton-Valentine leucocidin among community-acquired methicillin-resistant Staphylococcus aureus strains. J Clin Microbiol. 2005;43:3373-3379.
16. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004;38:1279-1286.
17. Infectious Disease Society of America (IDSA). Bad Bugs, No Drugs. As Antibiotic Discovery Stagnates. A Public Health Crisis Brews. Alexandria, Va: IDSA; 2004.
18. Hayden MK, Rezai K, Hayes RA, Lolans K, Quinn JP, Weinstein RA. Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005;43:5285-5287.
19. Vikram HR, Havill NL, Koeth LM, Boyce JM. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J Clin Microbiol. 2005;43:5384-5387.
20. Mangili A, Bica I, Snydman DR, Hamer DH. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058-1060.
21. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci. 2005;330:102-104.
22. Angell M. The Truth About Drug Companies: How They Deceive Us and What to Do About It. New York, NY: Random House; 2004.
23. Hiramatsu K, Cui L, Kuroda M, Ito T. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol. 2001;9:486-493.
24. Horowitz JB, Moehring HB. How property rights and patents affect antibiotic resistance. Health Econ. 2004;13:575-583.
25. Levy SB. Antibiotic resistance: consequences of inaction. Clin Infect Dis. 2001;33(suppl 3):S124-S129.
26. Dowling HF. The pharmaceutical industry and the doctor. What of the future? N Engl J Med. 1961;264:75-79.
27. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002;359:2188-2194.
28. Office of Legislative Policy and Analysis. Legislative updates. Available at: http://olpa.od.nih.gov/legislation/109/pendinglegislation/bioterror.asp. Accessed July 26, 2006.
29. Centers for Disease Control and Prevention. Get Smart: Know When Antibiotics Work. Available at: http://www.cdc.gov/drugresistance/community. Accessed November 15, 2005.
30. Alliance for the Prudent Use of Antibiotics. Home page. Available at: http://www.tufts.edu/med/apua. Accessed November 15, 2005.
31. O'Boyle CA, Henly SJ, Larson E. Understanding adherence to hand hygiene recommendations: the theory of planned behavior. Am J Infect Control. 2001;29:352-360.
32. Nash DR, Harman J, Wald ER, Kelleher KJ. Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections. Arch Pediatr Adolesc Med. 2002;156:1114-1119.
33. Projan SJ. Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol. 2003;6:427-430.
34. Shlaes DM. The abandonment of antibacterials: why and wherefore? Curr Opin Pharmacol. 2003;3:470-473.
35. Norrby SR, Nord CE, Finch R. Lack of development of new antimicrobial drugs: a potential serious threat to public health. Lancet Infect Dis. 2005;5:115-119.
36. Wenzel RP. The antibiotic pipeline - challenges, costs, and values. N Engl J Med. 2004;351:523-526.
37. Finland M, Kirby WM, Chabbert YA, et al. Round table: are new antibiotics needed? Antimicrobial Agents Chemother (Bethesda). 1965;5:1107-1114.